Guggenheim Reiterates Buy Rating for Oruka Therapeutics (NASDAQ:ORKA)

Key Points

• Guggenheim reiterated a Buy on Oruka Therapeutics with a $125 price target (about a 102.9% upside), and multiple other analysts have raised targets leaving a consensus near $74.90 and an overall "Moderate Buy" rating.
• Recent trading and fundamentals: ORKA traded at $61.60 (up ~3.4%), with a market cap of ~$3.05B; the company reported Q1 EPS of -$0.45 (beating estimates) while analysts forecast about -3.41 EPS for the year.
• Insider and institutional activity: Insiders sold ~23,765 shares (~$850k) in the last three months but still own ~24.7% of shares, while institutional investors hold ~56.4%, including notable increases by Invesco and RTW.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report)'s stock had its "buy" rating reissued by analysts at Guggenheim in a note issued to investors on Monday,Benzinga reports. They currently have a $125.00 price objective on the stock. Guggenheim's price objective would indicate a potential upside of 102.94% from the company's current price.

ORKA has been the topic of several other reports. BTIG Research lifted their target price on Oruka Therapeutics from $73.00 to $78.00 and gave the stock a "buy" rating in a report on Monday. HC Wainwright lifted their target price on Oruka Therapeutics from $40.00 to $70.00 and gave the stock a "buy" rating in a report on Monday. Piper Sandler assumed coverage on Oruka Therapeutics in a report on Thursday, December 18th. They set an "overweight" rating and a $75.00 target price on the stock. UBS Group lifted their target price on Oruka Therapeutics from $50.00 to $75.00 and gave the stock a "buy" rating in a report on Monday, April 6th. Finally, Stifel Nicolaus lifted their target price on Oruka Therapeutics from $47.00 to $72.00 and gave the stock a "buy" rating in a report on Friday, March 13th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Oruka Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $74.90.

Oruka Therapeutics Stock Up 3.4%

ORKA traded up $2.02 during midday trading on Monday, hitting $61.60. 204,396 shares of the company were exchanged, compared to its average volume of 613,519. The firm has a market capitalization of $3.05 billion, a P/E ratio of -33.09 and a beta of -0.54. Oruka Therapeutics has a 1-year low of $7.62 and a 1-year high of $64.61. The firm's 50 day moving average price is $39.53 and its 200-day moving average price is $32.31.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its earnings results on Thursday, March 12th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.16. On average, sell-side analysts predict that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Insider Transactions at Oruka Therapeutics

In other news, CEO Lawrence Otto Klein sold 1,729 shares of the business's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $41.30, for a total value of $71,407.70. Following the transaction, the chief executive officer directly owned 927,309 shares of the company's stock, valued at $38,297,861.70. The trade was a 0.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Joana Goncalves sold 7,641 shares of the business's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $40.91, for a total value of $312,593.31. Following the completion of the transaction, the insider directly owned 33,377 shares in the company, valued at $1,365,453.07. This represents a 18.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 23,765 shares of company stock worth $849,575 over the last three months. 24.69% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd bought a new position in Oruka Therapeutics in the fourth quarter worth approximately $67,000. Seven Fleet Capital Management LP bought a new stake in Oruka Therapeutics during the 4th quarter worth approximately $159,000. Invesco Ltd. increased its holdings in Oruka Therapeutics by 777.1% during the 4th quarter. Invesco Ltd. now owns 143,121 shares of the company's stock worth $4,338,000 after purchasing an additional 126,803 shares in the last quarter. Virtus Investment Advisers LLC bought a new stake in Oruka Therapeutics during the 4th quarter worth approximately $267,000. Finally, RTW Investments LP increased its holdings in Oruka Therapeutics by 5.8% during the 4th quarter. RTW Investments LP now owns 2,058,148 shares of the company's stock worth $62,382,000 after purchasing an additional 112,499 shares in the last quarter. Institutional investors own 56.44% of the company's stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.